Nancy A. Grygiel, Senior Vice President and Chief Compliance Officer at Amgen Inc . (NASDAQ:AMGN), recently sold shares of the company's common stock. According to a filing with the Securities and ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up ...

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of ...

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets. The ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Amgen has demonstrated solid financial performance in recent ... InvestingPro analysis suggests the stock is trading close to its Fair Value, with additional insights available to subscribers. EPS ...

Amgen has demonstrated solid financial performance ... InvestingPro analysis suggests the stock is trading close to its Fair Value, with additional insights available to subscribers.